1. Conversion of mouse fibroblasts into oligodendrocyte progenitor-like cells through a chemical approach
- Author
-
Yawen Li, Jinke Cheng, Wenlin Li, Nan Cao, Chang Liu, Mingliang Zhang, Saiyong Zhu, Wenjie Lu, Sheng Ding, and Xu Hu
- Subjects
Epithelial-Mesenchymal Transition ,oligodendrocyte progenitor-like cells ,Cell ,Biology ,Regenerative medicine ,Mice ,Neural Stem Cells ,Genetics ,medicine ,demyelinating diseases ,Animals ,Cellular Reprogramming Techniques ,Axon ,Molecular Biology ,reprogramming ,Cell Biology ,General Medicine ,Fibroblasts ,Embryonic stem cell ,Neural stem cell ,Cell biology ,Transplantation ,cell fate conversion ,stomatognathic diseases ,small molecules ,Oligodendroglia ,medicine.anatomical_structure ,nervous system ,Original Article ,Neuron ,Reprogramming - Abstract
Transplantation of oligodendrocyte progenitor cells (OPCs) is a promising way for treating demyelinating diseases. However, generation of scalable and autologous sources of OPCs has proven difficult. We previously established a chemical condition M9 that could specifically initiate neural program in mouse embryonic fibroblasts. Here we found that M9 could induce the formation of colonies that undergo mesenchymal-to-epithelial transition at the early stage of reprogramming. These colonies may represent unstable and neural lineage-restricted intermediates that have not established a neural stem cell identity. By modulating the culture signaling recapitulating the principle of OPC development, these intermediate cells could be reprogrammed towards OPC fate. The chemical-induced OPC-like cells (ciOPLCs) resemble primary neural stem cell-derived OPCs in terms of their morphology, gene expression, and the ability of self-renewal. Upon differentiation, ciOPLCs could produce functional oligodendrocytes and myelinate the neuron axons in vitro, validating their OPC identity molecularly and functionally. Therefore, our study provides a non-integrating approach to OPC reprogramming that may ultimately provide an avenue to patient-specific cell-based or in situ regenerative therapy.
- Published
- 2019